Actuate Therapeutics Inc (ACTU) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
1751 River Run
Fort Worth, TX 76107
United States of America (the)
Phone
817 887 8455
Sector
Healthcare
Industry
Biotechnology
Employees
12
First IPO Date
August 13, 2024
| Name | Title | Pay | Year Born |
| Daniel Schmitt | Chief Executive Officer, President & Director | 712,329 | 1962 |
| Paul J. Lytle | Chief Financial Officer | 514,425 | 1968 |
| Andrew Mazar | Co-Founder & Chief Operating Officer | 552,150 | 1962 |
| Alan Kozikowski | Scientific Founder and Advisor | 0 | 1950 |
Actuate Therapeutics, Inc. is a biopharmaceutical firm operating at the clinical stage, dedicated to creating treatments for various cancers. Its primary drug candidate is Elraglusib Injection, an innovative glycogen synthase kinase-3 (GSK-3) inhibitor designed to combat metastatic pancreatic ductal adenocarcinoma. Furthermore, Elraglusib is being developed to address other malignancies, including Ewing sarcoma, metastatic melanoma, and colorectal cancer. Originally named Apotheca Therapeutics, Inc., the organization rebranded as Actuate Therapeutics, Inc. in October 2015. Established in 2015, the company maintains its headquarters in Fort Worth, Texas.